Drug profile · INN
erythromycin ethylsuccinate
E-MYCIN 200
erythromycin ethylsuccinate (E-MYCIN 200) is a bacterial 70s ribosome inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — erythromycin ethylsuccinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 9
- Data quality
- 0.89
Quick answer
erythromycin ethylsuccinate (E-MYCIN 200) is a bacterial 70s ribosome inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is erythromycin ethylsuccinate?
erythromycin ethylsuccinate (E-MYCIN 200) is a bacterial 70s ribosome inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for erythromycin ethylsuccinate?
E-MYCIN 200 is a marketed brand name for erythromycin ethylsuccinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of erythromycin ethylsuccinate?
erythromycin ethylsuccinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.